[go: up one dir, main page]

Dasgupta, 2016 - Google Patents

Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants

Dasgupta, 2016

Document ID
5363540937800073184
Author
Dasgupta A
Publication year
Publication venue
Personalized immunosuppression in transplantation

External Links

Snippet

Although immunoassays are widely used for therapeutic drug monitoring of various immunosuppressants, a major limitation of these immunoassays is the significant cross- reactivity with various metabolites of these agents. Some immunosuppressants, such as …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)

Similar Documents

Publication Publication Date Title
Dasgupta Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants
EP2174137B1 (en) Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites
Holt et al. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force
Noll et al. Validation of an LC–MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies
Pieri et al. Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors
Dasgupta Impact of interferences including metabolite crossreactivity on therapeutic drug monitoring results
Wilson et al. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus
Hieu et al. Determination of tacrolimus in human whole blood in kidney transplant recipients using a rapid and specific LC–MS/MS method
De et al. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods
Tempestilli et al. Low plasma concentrations of albumin influence the affinity column–mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation
JP2001514737A (en) Pretreatment reagent and method of using it
US20240208996A1 (en) Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof
De Nicolò et al. Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?
Taylor et al. A High-throughput Hplc-ms/ms Method For Tacrolimus Measurement: 176
Strom et al. Cross-reactivity Of The Major Everolimus Hydroxy Metabolites With The Innofluor® Certican® Immunoassay For Clinical Tdm Of Everolimus: 125
Yang et al. A Simple And Rapid High-performance Liquid Chromatographic Procedure for Determination Of Inosine 5'-monophosphate Dehydrogenase Activity in Isolated Human Mononuclear Blood Cells (Mbc): 164
Steimer et al. Intermediate Metabolizers And Increased Risk Of Adverse Events in Psychiatric In-patients. an Update Including All Relevant Alleles With Reduced Function and Applying Gene-dose for Analysis: 170
Yip et al. High Sensitivity Method For The Measurement Of Acetaminophen In Plasma And Cerebrospinal Fluid Samples By Uv-hplc And Emit Immunoassay: 196
Lorenz et al. Determination Of Inosine Triphosphate Pyrophosphohydrolase (ITPA) Phenotype in Isolated Human Erythrocytes Using A Convenient New Hplc Procedure: 163
Solari et al. Rifampicin can alter pharmacokinetics of busulfan in patients given bone marrow transplantation: 167
Dervieux et al. Drug metabolite monitoring of azathioprine/6-MP therapy: contribution of thiopurine methyltransferase gene polymorphisms: 69
Zhang et al. Changes Of Brain Npy And Its Receptors In Rats With Flurazepam Tolerance And Dependence: 199
Saint-Marcoux et al. Pharmacokinetics Of Cyclosporine And Development Of A Bayesian Estimator In Heart, Lung And Renal Transplant Patients: A Nonmem Analysis: 154
Kapur et al. Free And Bound Enantiomers Of Methadone And Its Metabolite Eddp In Stable And Unstable Patients: 146
Jiang et al. Setting Up PPK/PD Model Of VPA In Children With Epilepsy By Nonmem Software: 50